Compare FENG & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FENG | PASG |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | China | United States |
| Employees | N/A | 27 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 19.2M |
| IPO Year | 2011 | 2020 |
| Metric | FENG | PASG |
|---|---|---|
| Price | $1.56 | $5.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 8.8K | ★ 37.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.53 | $0.35 |
| 52 Week High | $3.65 | $20.00 |
| Indicator | FENG | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 50.53 |
| Support Level | N/A | $4.94 |
| Resistance Level | $1.82 | $5.92 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 12.50 | 65.65 |
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.